At Xyphos, we’re working to deliver flexible and adaptable cancer therapies with the potential to revolutionize cancer care.

Xyphos’ proprietary convertibleCAR™ (Chimeric Antigen Receptor) technology creates flexible cell therapies that can be engineered and re-engineered inside the body to target more than …

The xiphos (Ancient Greek: ξίφος [ksípʰos]; plural xiphe, Ancient Greek: ξίφη [ksípʰɛː]) [1] is a double-edged, one-handed Iron Age straight shortsword used by the ancient Greeks. It was a …

We contribute to establishing a robust and competitive Cancer Cell Therapy pipeline at Astellas. Accurate as of April 2024. Programs listed above include programs of other Astellas affiliates …

Dec 27, 2019 · Xyphos has developed a flexible and versatile synthetic biology platform to direct cells of the immune system to target single or multiple tumor antigens while controlling the …

Feb 16, 2024 · Xyphos Biosciences, Inc., located at South San Francisco, Calif., is a wholly owned subsidiary of Astellas featuring ACCELTM technology, a CAR (chimeric antigen …

Dec 27, 2019 · Astellas Pharma has acquired Xyphos Biosciences for up to $665 million, the companies said today, in a deal intended to bolster the buyer’s cancer immunotherapy pipeline …

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones …

Dec 27, 2019 · TOKYO (Reuters) - Astellas Pharma Inc <4503.T> has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million …

Backed by strong issued and pending patents, Xyphos is merging cellular and antibody therapeutics to achieve safety, efficacy and versatility – ultimately bringing promising therapies …